- Home
- SYBX vs APM Comparison
SYBX vs APM Comparison
Compare SYBX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- APM
- Stock Information
- Founded
- SYBX N/A
- APM 2010
- Country
- SYBX United States
- APM United Kingdom
- Employees
- SYBX N/A
- APM N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- APM Health Care
- Exchange
- SYBX Nasdaq
- APM Nasdaq
- Market Cap
- SYBX 16.4M
- APM 18.9M
- IPO Year
- SYBX N/A
- APM 2018
- Fundamental
- Price
- SYBX $1.59
- APM $1.98
- Analyst Decision
- SYBX
- APM
- Analyst Count
- SYBX 0
- APM 0
- Target Price
- SYBX N/A
- APM N/A
- AVG Volume (30 Days)
- SYBX 19.9K
- APM 20.5M
- Earning Date
- SYBX 11-11-2025
- APM 04-30-2025
- Dividend Yield
- SYBX N/A
- APM N/A
- EPS Growth
- SYBX N/A
- APM N/A
- EPS
- SYBX N/A
- APM N/A
- Revenue
- SYBX N/A
- APM N/A
- Revenue This Year
- SYBX N/A
- APM N/A
- Revenue Next Year
- SYBX N/A
- APM N/A
- P/E Ratio
- SYBX N/A
- APM N/A
- Revenue Growth
- SYBX N/A
- APM N/A
- 52 Week Low
- SYBX $0.90
- APM $0.46
- 52 Week High
- SYBX $1.96
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- SYBX 64.64
- APM 52.67
- Support Level
- SYBX $1.45
- APM $1.64
- Resistance Level
- SYBX $1.54
- APM $2.65
- Average True Range (ATR)
- SYBX 0.06
- APM 0.21
- MACD
- SYBX 0.01
- APM -0.05
- Stochastic Oscillator
- SYBX 94.74
- APM 33.66
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.